New Advances, Clinical Opportunities, and Current Challenges in Treating Adults With Ph-Negative ALL: Webcast

View this on-demand Webcast, read expert-authored ClinicalThought commentaries, or download the slides to review key data and representative patient cases that highlight new and emerging immunotherapy treatments for ALL.

Matthew Wieduwilt, MD, PhD

ClinicalThought

The FDA approvals of blinatumomab, inotuzumab ozogamicin, and tisagenlecleucel have expanded our treatment options for relapsed/refractory ALL. Read my take on where these immunotherapies most benefit our patients and what they may offer us in future clinical practice.

Matthew Wieduwilt, MD, PhD Released: September 20, 2018
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

This activity is supported by educational grants from
Amgen
Pfizer Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?